Cargando…

Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study

Serum autoantibodies respond not only to tumor-associated antigens of hepatocellular carcinoma (HCC) but also to those of liver cirrhosis (LC) and chronic hepatitis (CH). The present prospective multi-institutional study evaluated the diagnostic properties of six autoantibodies in distinguishing HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Rei, Otsuka, Yuichiro, Yokosuka, Osamu, Kato, Naoya, Imazaki, Fumio, Hoshino, Isamu, Sugiura, Nobuyuki, Mizumoto, Hideaki, Azemoto, Ryousaku, Kato, Kazuki, Shimada, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494420/
https://www.ncbi.nlm.nih.gov/pubmed/36238856
http://dx.doi.org/10.3892/ol.2022.13487
_version_ 1784793792790921216
author Okada, Rei
Otsuka, Yuichiro
Yokosuka, Osamu
Kato, Naoya
Imazaki, Fumio
Hoshino, Isamu
Sugiura, Nobuyuki
Mizumoto, Hideaki
Azemoto, Ryousaku
Kato, Kazuki
Shimada, Hideaki
author_facet Okada, Rei
Otsuka, Yuichiro
Yokosuka, Osamu
Kato, Naoya
Imazaki, Fumio
Hoshino, Isamu
Sugiura, Nobuyuki
Mizumoto, Hideaki
Azemoto, Ryousaku
Kato, Kazuki
Shimada, Hideaki
author_sort Okada, Rei
collection PubMed
description Serum autoantibodies respond not only to tumor-associated antigens of hepatocellular carcinoma (HCC) but also to those of liver cirrhosis (LC) and chronic hepatitis (CH). The present prospective multi-institutional study evaluated the diagnostic properties of six autoantibodies in distinguishing HCC from LC and CH. A total of 416 participants were enrolled: 149 With HCC, 76 with LC, 103 with CH and 88 healthy controls. Titers of serum autoantibodies to Sui1, RalA, p62, p53, c-myc and NY-ESO-1 were determined using enzyme-linked immunosorbent assays. All six antibodies were positive for HCC: s-Sui1-Abs (44%), s-RalA-Abs (23%), s-p62-Abs (21%), s-p53-Abs (13%), s-c-myc-Abs (11%) and s-NY-ESO-1-Abs (6%). The positivity rates of all six antibodies combined were 5% for healthy controls, 52% for CH, 58% for LC and 66% for HCC. The positivity rates of s-Sui1-Abs, s-RalA-Abs and s-p53-Abs were higher for HCC compared with those of LC and CH. However, the positivity rates of s-p62-Abs, s-c-myc-Abs and s-NY-ESO-1-Abs for HCC were not higher compared with those for LC and CH. Overall, autoantibodies were useful in differentiating patients with HCC from healthy individuals. However, they were not specific to HCC and were also present in the sera of individuals with CH and LC. These autoantibodies may be induced during the development of HCC. Clinical trial registration number: UMIN000014530 (date of registration 2011/07/11).
format Online
Article
Text
id pubmed-9494420
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-94944202022-10-12 Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study Okada, Rei Otsuka, Yuichiro Yokosuka, Osamu Kato, Naoya Imazaki, Fumio Hoshino, Isamu Sugiura, Nobuyuki Mizumoto, Hideaki Azemoto, Ryousaku Kato, Kazuki Shimada, Hideaki Oncol Lett Articles Serum autoantibodies respond not only to tumor-associated antigens of hepatocellular carcinoma (HCC) but also to those of liver cirrhosis (LC) and chronic hepatitis (CH). The present prospective multi-institutional study evaluated the diagnostic properties of six autoantibodies in distinguishing HCC from LC and CH. A total of 416 participants were enrolled: 149 With HCC, 76 with LC, 103 with CH and 88 healthy controls. Titers of serum autoantibodies to Sui1, RalA, p62, p53, c-myc and NY-ESO-1 were determined using enzyme-linked immunosorbent assays. All six antibodies were positive for HCC: s-Sui1-Abs (44%), s-RalA-Abs (23%), s-p62-Abs (21%), s-p53-Abs (13%), s-c-myc-Abs (11%) and s-NY-ESO-1-Abs (6%). The positivity rates of all six antibodies combined were 5% for healthy controls, 52% for CH, 58% for LC and 66% for HCC. The positivity rates of s-Sui1-Abs, s-RalA-Abs and s-p53-Abs were higher for HCC compared with those of LC and CH. However, the positivity rates of s-p62-Abs, s-c-myc-Abs and s-NY-ESO-1-Abs for HCC were not higher compared with those for LC and CH. Overall, autoantibodies were useful in differentiating patients with HCC from healthy individuals. However, they were not specific to HCC and were also present in the sera of individuals with CH and LC. These autoantibodies may be induced during the development of HCC. Clinical trial registration number: UMIN000014530 (date of registration 2011/07/11). D.A. Spandidos 2022-08-31 /pmc/articles/PMC9494420/ /pubmed/36238856 http://dx.doi.org/10.3892/ol.2022.13487 Text en Copyright: © Okada et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Okada, Rei
Otsuka, Yuichiro
Yokosuka, Osamu
Kato, Naoya
Imazaki, Fumio
Hoshino, Isamu
Sugiura, Nobuyuki
Mizumoto, Hideaki
Azemoto, Ryousaku
Kato, Kazuki
Shimada, Hideaki
Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study
title Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study
title_full Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study
title_fullStr Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study
title_full_unstemmed Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study
title_short Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study
title_sort six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: a prospective multi-institutional study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494420/
https://www.ncbi.nlm.nih.gov/pubmed/36238856
http://dx.doi.org/10.3892/ol.2022.13487
work_keys_str_mv AT okadarei sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT otsukayuichiro sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT yokosukaosamu sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT katonaoya sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT imazakifumio sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT hoshinoisamu sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT sugiuranobuyuki sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT mizumotohideaki sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT azemotoryousaku sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT katokazuki sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy
AT shimadahideaki sixautoantibodiesaspotentialdifferentialbiomarkersofhepatocellularcarcinomavslivercirrhosisandchronichepatitisaprospectivemultiinstitutionalstudy